First Choice of Antihypertensive Therapy

Authors

  • Haralambos Gavras Boston University School of Medicine, Boston, MA, USA

DOI:

https://doi.org/10.2015/hc.v3i4.284

Abstract

The first choice of antihypertensive therapy should include an agent with the best metabolic profile, usually an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), but additional agents should be used as needed to attain optimal blood pressure control, usually a diuretic or calcium-channel blocker (CCB) or both, whereas β-blockers should be used only if specially indicated for co-morbidities, such as in cases of coexisting coronary disease or chronic heart failure.

Author Biography

Haralambos Gavras, Boston University School of Medicine, Boston, MA, USA

Specialty: Cardiology

Downloads

Issue

Vol. 3 No. 4 (2008)

Section

EDITORIAL

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).